当前位置: X-MOL 学术J. Gynecol. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).
Journal of Gynecologic Oncology ( IF 3.4 ) Pub Date : 2021-01-27 , DOI: 10.3802/jgo.2021.32.e31
Yong Jae Lee 1 , Myong Cheol Lim 2, 3, 4 , Byoung Gie Kim 5 , Natalie Yl Ngoi 6 , Chel Hun Choi 5 , Sang Yoon Park 4 , David Sp Tan 6, 7 , Yunjung Go 1 , Jung Yun Lee 1
Affiliation  

The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in BRCA wild-type patients with platinum-sensitive recurrence. We hypothesized that adding pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free survival (PFS) in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer.

中文翻译:

在铂敏感复发性卵巢癌的 BRCA 非突变患者中使用帕博利珠单抗和贝伐珠单抗维持奥拉帕利的单臂 II 期研究 (OPEB-01)。

BRCA野生型铂敏感复发性卵巢癌患者的最佳治疗方案仍然未知。最近,越来越多的证据支持聚(二磷酸腺苷-核糖)聚合酶抑制剂、抗血管生成药物和免疫疗法的组合作为铂敏感复发的BRCA野生型患者的维持治疗。我们假设在奥拉帕利维持治疗中加入派姆单抗和贝伐单抗可以提高BRCA野生型铂敏感复发性卵巢癌患者的无进展生存期 (PFS) 。
更新日期:2021-02-11
down
wechat
bug